Transforming blood cancer care to make a difference for patients

AstraZeneca’s Gemma Satterthwaite talks to the company’s ambition to transform the entire care experience for patients with blood cancers.

Dec. 4, 2023

How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times

John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.

By Michael Gibney • Nov. 30, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

By Jonathan Gardner • Nov. 29, 2023

Organon’s chief medical officer wants to change how the world sees women’s health

Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.

By Michael Gibney • Nov. 22, 2023

The biopharma COO’s playbook

Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

By Alexandra Pecci • Nov. 21, 2023

6 ways to improve clinical trial diversity — as shown by J&J

Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

By Alexandra Pecci • Nov. 14, 2023

Optimizing KOL engagement and technology utilization in 2024

What if your advisory solution was a skillful blend of innovative tech, medical communications specialists, high-touch client service, and a flexible contract?

Nov. 13, 2023

5 of the best paid biopharma CEOs

As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

By Alexandra Pecci • Nov. 10, 2023

Does BioMarin’s CEO shuffle signal bigger changes ahead?

With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.

By Meagan Parrish • Nov. 9, 2023

How pharma leaders talk about ethics in a highly criticized industry

The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?

By Michael Gibney • Nov. 9, 2023

A new delivery method muscling its way into the RNA space

With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

By Kelly Bilodeau • Nov. 8, 2023

How Big Pharma keeps the oncology engines hot with a host of strategies

From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.

By Michael Gibney • Nov. 2, 2023

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

Roivant Sciences CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities.

By Michael Gibney • Oct. 31, 2023

Red Jacket: Dr. Mark Goldberg, a clinical innovator

Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.

By Alexandra Pecci • Oct. 27, 2023

The 2023 Red Jacket honorees

This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

By Meagan Parrish • Oct. 27, 2023

Red Jacket: Dr. Jeremy Levin, a transformational leader

A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.

By Michael Gibney • Oct. 27, 2023

Red Jacket: Helen Sabzevari, an immunotherapy pioneer

Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

By Meagan Parrish • Oct. 27, 2023

Red Jacket: Adele Gulfo, a commercialization guru

With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

By Karissa Waddick • Oct. 27, 2023

Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

By Michael Gibney • Oct. 19, 2023

The top biopharma conferences in 2024

A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

By Ned Pagliarulo • Oct. 16, 2023

PharmaVoice 100s: Rare disease warriors

Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

By Michael Gibney • Oct. 16, 2023

Branded: The trademarks pharma leaders look up to

What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

By PharmaVoice Staff • Oct. 13, 2023

5 minutes with — IDEA Pharma’s Mike Rea

The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

By Meagan Parrish • Oct. 11, 2023

Key upcoming events for pharma execs

Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

By Meagan Parrish • Oct. 6, 2023

FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

By Michael Gibney • Oct. 5, 2023